发明授权
US5968753A Positive and positive/negative cell selection mediated by peptide release
失效
由肽释放介导的阳性和阳性/阴性细胞选择
- 专利标题: Positive and positive/negative cell selection mediated by peptide release
- 专利标题(中): 由肽释放介导的阳性和阳性/阴性细胞选择
-
申请号: US482228申请日: 1995-06-07
-
公开(公告)号: US5968753A公开(公告)日: 1999-10-19
- 发明人: Janet Tseng-Law , Joan A. Kobori , Fahad A. Al-Abdaly , Roy Guillermo , Sam L. Helgerson , Robert J. Deans
- 申请人: Janet Tseng-Law , Joan A. Kobori , Fahad A. Al-Abdaly , Roy Guillermo , Sam L. Helgerson , Robert J. Deans
- 申请人地址: CA Irvine
- 专利权人: Nexell Therapeutics, Inc.
- 当前专利权人: Nexell Therapeutics, Inc.
- 当前专利权人地址: CA Irvine
- 主分类号: G01N33/53
- IPC分类号: G01N33/53 ; C07K1/04 ; C07K5/113 ; C07K7/06 ; C07K7/08 ; C07K7/64 ; C07K14/705 ; C07K16/28 ; C07K16/30 ; C12N5/00 ; C12N5/06 ; C12N15/00 ; C12N15/09 ; C12P21/08 ; C12R1/91 ; G01N33/569 ; G01N33/577 ; G01N33/567 ; C07K4/00 ; C07K5/00
摘要:
The invention provides a non-enzymatic method for the release of cells which have been positively selected from a heterogeneous cell suspension by antibody-mediated binding to beads or other solid support. The method entails forming within the cell suspension a complex comprising the solid support linked to a primary antibody, which in turn is specifically bound to a cell surface antigen on the target cells. The complex is separated from the cell suspension, and then contacted with a specific peptide which binds to the primary antibody, displacing the antibody from the cell surface antigen, thereby releasing the target cell from the complex. The invention also provides methods for positive/negative cell selection wherein target cells having a first antigen are selected from a heterogeneous cell suspension containing undesired cells having a second antigen. The invention also provides methods for identifying a specific peptide useful for the release of a target cell from the binding of a specific primary antibody. The methods of the invention are particularly useful for the positive selection of CD34+ hematopoietic stem cells and the concomitant purging of undesired tumor cells or lymphocytes from the positively selected cell population. The purified CD34+ cell composition is then useful for reinfusion to a cancer patient after high-dose therapy in order to reconstitute the patient's immune system.
公开/授权文献
- US5052567A Bottle with a gripping recess 公开/授权日:1991-10-01
信息查询
IPC分类: